Translocator protein (18 kDa), formerly known as the peripheral benzodiazepine receptor (PBR), has been extensively used as a biomarker of active brain disease and neuroinflammation. TSPO expression increases dramatically in glial cells, particularly in microglia and astrocytes, as a result of brain injury, and this phenomenon is a component of the hallmark response of the brain to injury. In this study, we used a mouse model of Sandhoff disease (SD) to assess the longitudinal expression of TSPO as a function of disease progression and its relationship to behavioral and neuropathological endpoints. Focusing on the presymptomatic period of the disease, we used ex vivo [ ]IodoDPA-713 small animal SPECT imaging to show that brain TSPO levels markedly increase prior to physical and behavioral manifestation of disease. We further show that TSPO upregulation coincides with early neuronal GM2 ganglioside aggregation and is associated with ongoing neurodegeneration and activation of both microglia and astrocytes. In brain regions with increased TSPO levels, there is a differential pattern of glial cell activation with astrocytes being activated earlier than microglia during the progression of disease. Immunofluorescent confocal imaging confirmed that TSPO colocalizes with both microglia and astrocyte markers, but the glial source of the TSPO response differs by brain region and age in SD mice. Notably, TSPO colocalization with the astrocyte marker GFAP was greater than with the microglia marker, Mac-1. Taken together, our findings have significant implications for understanding TSPO glial cell biology and for detecting neurodegeneration prior to clinical expression of disease.
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Introduction
Sandhoff disease (SD) is an autosomal recessive disorder characterized by a deficiency in the lysosomal enzyme β-hexosaminidase, which leads to the accumulation of gangliosides and glycolipids, specifically GM2 and GA2 (Jeyakumar et al., 2002; Mahuran, 1999) . Because gangliosides are expressed at high levels in the central nervous system (CNS), the brain is one of the most affected organs (Jeyakumar et al., 2002) . Ganglioside accumulation in the brain ultimately leads to progressive and widespread neurodegeneration and motor impairments (Wada et al., 2000) . In humans, the onset of the infantile form of SD occurs around 6 months of age with symptoms such as motor weakness, early blindness, macroencephaly, and seizures. Symptoms progress rapidly, and death occurs between 3 to 5 years of age (Maegawa et al., 2006) . β-Hexosaminidase is formed by the dimerization of two subunits, α-and β-subunits to form β-hexosaminidase A (αβ) or two β subunits to form β-hexosaminidase B (ββ). In the mouse model of SD, the gene encoding for the β subunit of β-hexosaminidase (Hexb) is disrupted, resulting in the deficiency of both β-hexosaminidase A and B (Yamanaka et al., 1994) . This deficiency leads to impaired degradation and subsequent accumulation of GM2 and GA2 gangliosides in neurons (Sango et al., 1995; Jeyakumar et al., 2002; Mahuran, 1999) , resulting in severe neurodegeneration in the brain (Wada et al., 2000) . Sandhoff (Hexb KO) mice exhibit spastic and reduced hind limb movements with progressive motor deficits starting at 3 months of age (Sango et al., 1995) . The life span of SD mice is approximately 5 months of age as the mice lose the ability to move and are unable to retrieve food or water (Sango et al., 1995; Tifft and Proia, 1997; Jeyakumar Neurobiology of Disease 85 (2016) 174-186 
